A Gastroretentive floating controlled drug delivery system containing Silymarin was prepared in the form of tablets and evaluated for its processing parameters, in vitro release in 0.1 N HCl. Eight formulations were prepared by using rate controlling polymers such as HPMC K4M and Eudragit RS100, alkalizing agent sodium bicarbonate and solubilizing agent poly vinyl Pyrrolidone (PVP K30). Page 234 respectively and the formulations showed no significant changes in physical appearance, drug content and in-vitro drug release even after 60 days. The control release of the drug from the dosage form shows the hepatoprotective activity against Isoniazid (INH) + Rifampcin (RIF) induced hepatotoxicity in rats.
Introduction
Tuberculosis is one of the most common infectious diseases. In India, pulmonary tuberculosis is one of the major causes for adult deaths. Isoniazid (INH) and Rifampcin (RIF), the first line drugs used for tuberculosis chemotherapy are associated with hepatotoxicity 1 In view of this, the present study was aimed at evaluating the Hepatoprotective activity of Silymarin formulations against INH and RIF induced Hepatotoxicity in albino rats.
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MATERIAL AND METHODS Materials
Silymarin, Hydroxy propyl methyl cellulose (HPMC K4M) and Eudragit RS100 were obtained as gift sample from Micro Labs, Hosur. Polyvinyl pyrrolidone (PVP K30) was obtained from Granules India Ltd., Hyderabad. Other reagents and solvents were of analytical grade.
Method
Preparation of Silymarin floating tablets 3 The drug, polymers (at different ratios), PVP K30, sodium lauryl sulfate (SLS), sodium bicarbonate (NaHCO 3 ) and lactose were blended thoroughly in a motor and pestle and then passed through sieve no. 100. The powder blend was mixed with talc (2%) and tablets were prepared by direct compression method using a single punch-tableting machine (Minipress-I) with hardness 6 kg/cm 2 .
Eight formulations were prepared and coded them from F1 to F8. The details of composition of each formulation are shown in Table- INGREDIENTS  F1  F2  F3  F4  F5  F6  F7  F8   01.  SILYMARIN  280  280  280  280  280  280  280  280   02.  HPMC K4M  75  100  100  ------50  50   03.  EUDRAGIT RS 100  ------75  100  100  50  50   04.  NaHCO 3  70  70  70  70  70  70  70  70   05.  PVP K30  20  20  40  20  20  40  20  40   06.  SLS  3  3  3  3  3  3  3  3 07. 
EVALUATION OF GRANULES (OR) POWDER BLEND
Preformulation studies such as angle of repose, bulk density, tapped density, compressibility index and Hausner's ratio were determined for their micromeritic properties.
EVALUATION OF FLOATING TABLETS
To design tablets and tablets production quality, the formulated tablets were evaluated for hardness test 4 (using Monsanto Hardness Tester), friability test 5 (using Roche Friabilator) and weight variation test 6 .
Buoyancy / Floating test
7
The time interval between introduction of tablet into the dissolution medium and its floatation to the top of the dissolution medium was termed as buoyancy lag time (BLT). The duration upto which the tablet floats on the dissolution medium was taken as duration of buoyancy (DB). Both BLT and DB were determined using USP 24 type II dissolution apparatus in 900ml of 0.1N HCl at 37°±1°C.
Drug content
Five tablets from each formulation were taken and grinded into fine powder. 
IR Spectral Analysis
A drug-polymers interaction was studied by using FTIR 8 (Shimadzu, Japan, Model-8400s). IR Spectral Analysis of pure Silymarin, HPMC K4M, Eudragit RS100 were carried out. The peaks and the patterns produced by the pure drug were compared with peaks and patterns of pure drug with combination of polymers.
Dissolution studies 3 In vitro drug release of all the formulations were carried out using USP-type II dissolution apparatus (paddle type). The dissolution medium, 900 ml 0.1N HCl solution, was placed into the dissolution flask maintaining the temperature of 37 + 0. Drug release kinetics (Curve Fitting Analysis) 9, 10, 11 To analyze the mechanism of the drug release rate kinetics of the dosage form, the data obtained were fitted into zero order, first order, Higuchi's model and Korsmeyer's equation release models. The model with the highest correlation coefficient was considered to be the best model. The value of 'n' in the Korsmeyer's model indicates the release mechanism.
Stability studies 12 It was carried out to evaluate the stability of the drug. All the formulations were stored at 
Pharmacodynamic studies
Healthy Wister albino rats of either sex weighing about 150-200gm are selected and used in the present study. The animals were acclimatized for 2 weeks prior to experiment. The animals were free to access standard pellet food and water.
Isoniazid (INH) and Rifampcin (RIF) were used to produce hepatotoxicity in rats. INH and RIF were dissolved in sterile distilled water and administered at the dose of 12.5mg/kg body weight to 24 animals for14 days.
These above animals were divided into 4 groups [Group IIA, Group IIB, Group IIC and Group IID] and treated orally as follows:
• Group I: 6 rats were treated with 1ml of 1%w/v Carboxy Methyl Cellulose (CMC) for 14 days (normal control) at the dose of 12.5mg/kg body weight.
• Group II: 24 rats were treated with INH + RIF for 14 days (10mg/kg). On 15 th day these 24 animals were divided into 4 groups (i.e., IIA, IIB, IIC and IID).
• Group IIA: Among 24 animals treated with INH + RIF, 6animals were selected and served as hepatotoxic control and was not treated with any drug.
• Group IIB: 6 rats were treated with Silymarin tablets without polymer suspended in 1%w/v CMC at the dose of 12.5mg/kg body weight.
• Group IIC: 6 rats were treated with drug + HPMC K4M (F3) suspended in 1%w/v CMC at the dose of 12.5mg/kg body weight. • Group IID: 6 rats were treated with drug + Eudragit RS 100 (F6) suspended in 1%w/v CMC at the dose of 12.5mg/kg body weight.
Biochemical analysis
Several plasma proteins, including bilirubin, are synthesized in the liver, and the liver also regulates plasma lipids and lipoproteins. Therefore, the levels of total protein and total bilirubin can be used as indicators of liver function. Serum ALT, AST, ALP and GGTP activities are considered as good markers of hepatic injury and hepatocellular integrity. The activities of these enzymes before starting the treatment (as baseline values) and after the treatment of rats with the drugs are measured.
Blood samples obtained from tail vein was centrifuged for 10min at 3000rpm to separate the serum and serum samples were stored in a deep freezer until they could be analyzed. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma glutamyl-3-carboxy-4-nitroanilide (GGTP) activities and the levels of serum albumin, serum total protein, and serum total bilirubin were determined by Hitachi-917 auto-analyzer.
On the 15 th day, Group IIB, IIC and IID animals were treated with Silymarin tablet without polymer, Silymarin with HPMC K4M and Silymarin with Eudragit RS 100 respectively. After 7 hours of these drug treatments the blood samples were collected, centrifuged and serum samples were analyzed to determine the above parameters. The results are presented in Table- 
RESULTS AND DISCUSSION
The Silymarin floating tablets using two polymers and in combination of polymers with different ratios was prepared by direct compression method. Before compression of the powder, preformulation studies such as Bulk density, Tapped density, Angle of repose, Compressibility index and Hausner's ratio were determined for all formulations. All the parameters are within the acceptable limits for powder bled to show good flow properties while formulating tablets.
The tablets were prepared and evaluated for the hardness, friability, weight variation, drug it showed that levels of serum marker enzymes (AST, ALP, ALT and GGTP) and total bilirubin was decreased with increase in total protein. If the treatment is continued for 14 to 15 days serum marker enzymes, total bilirubin and total protein may reach the normal values.
From this study, Silymarin floating tablet formulations showed the significant protective action against hepatotoxic effect produced by Isoniazid (INH) and Rifampicin (RIF).
Conclusion
The present study was carried out to develop the floating drug delivery system using HPMC K4M and Eudragit RS100 polymers as carriers. The results of experimental studies of Silymarin floating tablets proved that the powder blend showed good flow properties, tablet evaluation tests are within the acceptable limits, IR spectral analysis proved that there was no drug-polymer interaction, percentage drug release was controlled and the formulations were stable after storing at different temperatures for 60 days. Thus, results of the current study clearly indicates, a promising potential of the Silymarin floating system as an alternative to the conventional dosage form. The Pharmacodynamic activity of Silymarin showed the protective action against hepatotoxicity in animals.
Further, clinical investigation of Silymarin floating tablets in human volunteers may improve the patient compliance. Such an attempt will be useful to release Silymarin floating drug delivery system in the market in the near future.
